Literature DB >> 35027136

The structures of two polysaccharides from Angelica sinensis and their effects on hepatic insulin resistance through blocking RAGE.

Wenjuan Liu1, Zezhi Li1, Caixia Feng1, Shengwei Hu1, Xin Yang1, Kaimin Xiao1, Qiuna Nong1, Qianhan Xiao1, Kehan Wu1, Xiao-Qiang Li2, Wei Cao3.   

Abstract

This study found two novel homogeneous polysaccharides from Angelica sinensis, APS-1I and APS-2II, binding to RAGE with a dissociation constant of 2.02 ± 0.2 and 85.92 ± 0.2 μM, respectively. APS-1I is a 17.0 kDa heteropolysaccharide, whose backbone is composed of α-1,6-Glcp, α-1,3,6-Glcp, α-1,2-Glcp, α-1,4-Galp, and α-1,3-Rhap, and whose two branches contain α-1,3,5-Araf, α-1,3-Araf, α-1,4-Galp, β-1,3-Galp, and β-1,4-Glcp. APS-2II is a 10.0 kDa linear glucan, that contains α-1,6-Glcp, α-1,3-Glcp, α-1,2-Glcp, and α-T-Glcp. In vitro, APS-1I demonstrated better promotion on glucose absorption and stronger repression on p-IRS-1 (Ser307), p-IRS-2 (Ser731), p-JNK, and p-P38 than APS-2II in insulin resistance (IR)-HepG2 cells. Furthermore, APS-1I treatment couldn't further decrease the inhibition on the phosphorylation of JNK and P38 produced by RAGE siRNA in IR-HepG2 cells. In vivo, APS-1I markedly improved IR and reversed the livers RAGE-JNK/p38-IRS signaling in high-fat-diet and streptozotocin-induced diabetic rats, suggesting that APS-1I could be a potential agent for improving IR in type 2 diabetes.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angelica sinensis; Insulin resistance; Polysaccharide; Structure; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 35027136     DOI: 10.1016/j.carbpol.2021.119001

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  1 in total

Review 1.  Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?

Authors:  Marta Wolosowicz; Slawomir Prokopiuk; Tomasz W Kaminski
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.